Dr Poon Thong Yuen LSWM 06 Jul 2018

HistoIndex Welcomes its New CEO on Board!

Date: 06 Jul 2018

HistoIndex has appointed Dr Poon Thong Yuen as its new Chief Executive Officer (CEO) with effect from 1 July 2018. Dr Poon takes over from Dr Gideon Ho, who will continue to drive the global business growth of the company as the Chief Commercial Officer (CCO).

Read More
The Progression of NAFLD HistoIndex 08 Jun 2018

A Worldwide Effort to Defeat Nonalcoholic Steatohepatitis (N...

Date: 08 Jun 2018

As part of the international NASH Education Program™, HistoIndex has joined over 150 world experts in a global call of action to promote the awareness of NASH in Singapore.

Read More
Thumbnail partnership 1 18 May 2018

HistoIndex and CymaBay Therapeutics Team Up to Advance NASH...

Date: 18 May 2018

Histoindex Pte. Ltd., with the world’s first stain-free Genesis®200 multiphoton digital pathology system, is collaborating with CymaBay Therapeutics, Inc. to evaluate the efficacy of seladelpar in a randomized, double-blind, placebo-controlled, multi-center Phase 2b study of 175 subjects with biopsy-confirmed Nonalcoholic Steatohepatitis (NASH).

Read More
HistoIndex Stain free Liver Tissue Image 11 Jan 2018

Histoindex's Stain-Free Digital Pathology System Receives HS...

Date: 11 Jan 2018

The stain-free Laennec® digital pathology imaging system by HistoIndex® has achieved its first regulated in vitro diagnostics (IVD) product status with the issuance of a Health Sciences Authority (HSA) Class A licence. This is a world’s first achievement for a stain-free digital pathology innovation to be approved for use in a clinical diagnosis setting. 

Read More
histoindex official1 04 Oct 2017

HistoIndex Receives Frost & Sullivan 2017 Asia-Pacific Best...

Date: 04 Oct 2017

Histoindex Pte. Ltd. has been presented with the 2017 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Diagnostics New Product Innovation Award by Frost & Sullivan. The award is a testament of the achievements by HistoIndex and the impact of its proprietary technologies such as Genesis®200 on aiding clinical diagnosis and the development of NASH therapeutics.

Read More
Signing Photo9 13 Jan 2016

HistoIndex Signs RMB15 million Co-investment Deal with JoinS...

Date: 13 Jan 2016

China-based Qingdao Yaozhu has entered into a joint venture agreement to co-invest with Singapore-headquartered medtech company, HistoIndex®.

Read More
hands 3127297 1920 10 Nov 2014

HistoIndex Partner Forms Strategic Partnership with GenScrip...

Date: 10 Nov 2014

PharmaNest announces a strategic partnership with GenScript, a leading biotech company in the USA, to offer services using HistoIndex's Genesis®200 smart pathology system for anti-fibrosis drug discovery.

Read More